WO2011095940A1 - Feeding composition comprising lemon oil - Google Patents
Feeding composition comprising lemon oil Download PDFInfo
- Publication number
- WO2011095940A1 WO2011095940A1 PCT/IB2011/050466 IB2011050466W WO2011095940A1 WO 2011095940 A1 WO2011095940 A1 WO 2011095940A1 IB 2011050466 W IB2011050466 W IB 2011050466W WO 2011095940 A1 WO2011095940 A1 WO 2011095940A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- bone marrow
- red blood
- blood cell
- liver
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 235000019501 Lemon oil Nutrition 0.000 title claims abstract description 7
- 239000010501 lemon oil Substances 0.000 title claims abstract description 7
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 23
- 210000003743 erythrocyte Anatomy 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 210000004185 liver Anatomy 0.000 claims abstract description 11
- 239000003921 oil Substances 0.000 claims abstract description 9
- 235000019198 oils Nutrition 0.000 claims abstract description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 8
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 8
- 230000008929 regeneration Effects 0.000 claims abstract description 8
- 238000011069 regeneration method Methods 0.000 claims abstract description 8
- 230000002411 adverse Effects 0.000 claims abstract description 7
- 150000001413 amino acids Chemical class 0.000 claims abstract description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 6
- 239000011707 mineral Substances 0.000 claims abstract description 6
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 claims abstract description 5
- -1 Magnisium Chemical compound 0.000 claims abstract description 5
- 239000004021 humic acid Substances 0.000 claims abstract description 5
- 229930003231 vitamin Natural products 0.000 claims abstract description 5
- 235000013343 vitamin Nutrition 0.000 claims abstract description 5
- 239000011782 vitamin Substances 0.000 claims abstract description 5
- 229940088594 vitamin Drugs 0.000 claims abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000010676 Ocimum basilicum Nutrition 0.000 claims abstract description 4
- 240000007926 Ocimum gratissimum Species 0.000 claims abstract description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 240000002657 Thymus vulgaris Species 0.000 claims abstract description 4
- 235000007303 Thymus vulgaris Nutrition 0.000 claims abstract description 4
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011575 calcium Substances 0.000 claims abstract description 4
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 4
- 239000010949 copper Substances 0.000 claims abstract description 4
- 229910052802 copper Inorganic materials 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229960000304 folic acid Drugs 0.000 claims abstract description 4
- 235000019152 folic acid Nutrition 0.000 claims abstract description 4
- 239000011724 folic acid Substances 0.000 claims abstract description 4
- 229910052742 iron Inorganic materials 0.000 claims abstract description 4
- 229930182817 methionine Natural products 0.000 claims abstract description 4
- 239000011574 phosphorus Substances 0.000 claims abstract description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract description 4
- 239000001585 thymus vulgaris Substances 0.000 claims abstract description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 4
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 4
- 239000011701 zinc Substances 0.000 claims abstract description 4
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 4
- 235000019482 Palm oil Nutrition 0.000 claims abstract description 3
- 239000002540 palm oil Substances 0.000 claims abstract description 3
- 241000287828 Gallus gallus Species 0.000 claims description 18
- 235000013330 chicken meat Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 244000144977 poultry Species 0.000 claims description 5
- 235000013594 poultry meat Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 3
- 235000020188 drinking water Nutrition 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 229920002527 Glycogen Polymers 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000003278 egg shell Anatomy 0.000 description 2
- 230000025215 erythrocyte homeostasis Effects 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000003307 slaughter Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108010028777 Complement C8 Proteins 0.000 description 1
- 102000016916 Complement C8 Human genes 0.000 description 1
- 108010027644 Complement C9 Proteins 0.000 description 1
- 102100031037 Complement component C9 Human genes 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061217 Infestation Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Definitions
- Feeding composition comprising lemon oil
- the invention relates to a composition which will assist the regeneration of the red blood cell mass in the bone marrow and/or act against adverse fatty changes in both the liver and bone marrow.
- the composition is for treatment of poultry and specifically chickens.
- New research in the poultry industry indicates a vertical transfer of pathogenic organisms from the parent stock to the new eggs being laid. This has a detrimental result on the condition of chicks hatched and delivered to the industry.
- fatty changes in the liver cells and in the bone marrow account for reduced production of albumin, acute phase proteins and glycogen. The latter is an important energy source needed in the pipping stage, to pierce the egg shell when hatching.
- the dormant pathogen infection occurs particularly in the macrophage phagocytic cells of the bone marrow. This has been determined in day-old chickens according to the so-called DMII (Dormant macrophage infestation index).
- DMII Densmant macrophage infestation index
- the dormant pathogens are usually activated during episodes of stress. The result is a direct suppressing effect on the whole immune system. This hampers any response to elimination of the underlying infections as well as in dealing with new infections that occur from time to time during the growth phase of the chickens.
- pathogens are bacterial organisms which bind directly to the la antigen locus on the surface of the red blood cell cytoplasmic membrane. This complex forms a hapten to stimulate antibody production. The hapten binds to the complex and with the addition of complement C8 and C9, small holes are dissolved into the cytoplasmic membrane. As a result, hemoglobin leakage from the cytoplasm of the red blood cell which causes depletion of red blood cell hemoglobin.
- the existence of the chicken is overwhelmed by: the attack on the red blood cell haemopoiesis (as seen in the form of a Type II immune response) with ultimate haemolysis of the red blood cells and induced anemia; and the physiological suppression of new cell development in the bone marrow and in the liver as a result of secondary fat infiltration with glycogen energy depletion.
- a composition to assist in the regeneration of the red blood cell mass in the bone marrow and act against adverse fatty changes in the liver and/or bone marrow comprising Lemon oil in combination with oils selected from Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John's Wort oil together with a carrier.
- the invention further provides for the carrier to be selected from Humic Acid or Palm oil; and for the composition to be used for the treatment of poultry and, in particular, chickens.
- a further feature of the invention provides for the composition to include amino acids; preferably Methionine and/or Tyrosine.
- composition to include a combination of vitamins and minerals selected from Calcium, Magnesium, Zinc, Iron, Copper, Phosphorus, Piridoxine, Folic Acid and Vitamin B12.
- compositions to be administered as a food additive or as a water soluble solution added to drinking water.
- the composition may also be provided and administered as capsules.
- the dosage is calculated at 10g of the composition per 100kg live body weight per day for the first week and 2g per 100kg thereafter.
- composition in accordance with this invention is made up of a combination of natural essential oils and has as its carrier Natural Humic Acid.
- the main ingredient is Lemon oil and this is used in combination with other essential oils selected from the group comprising Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John's Wart oil.
- the oils are dissolved in 96% Ethanol together with Polysorbate 60.
- the Polysorbate is added as an emulsifier. It assists in the proper dissolution of the constituent aromatic oils in water to provide the required solution.
- the solution is sprayed onto the granular Humic Acid. A residue of the oils remains on evaporation of the Ethanol.
- Methionine and Tyrosine are two amino acids that assist in the regeneration of the heart homeostasis and therefore serve to counteract heart failure. They also have the effect of activating the metabolism as a whole. In this sense, these amino acids break down fatty infiltration and change these molecules in the Krebs cycle into protein.
- a mixture of two further amino acids in the form of Arginine and Ornithine together with minerals in the form of Calcium, Magnesium, Copper, Zinc, Iron and Phosphorus and vitamins Pyridoxine, Folic acid and Vitamin B12 are also included.
- the Lemon oil provides the composition with the ability to regenerate and/or stimulate new red blood cell production in the bone marrow.
- the minerals (and/or other electrolytes) that are included in the composition serve to restore red blood cell homeostasis for oxygen delivery to organs.
- the composition of this invention is directed on the one hand to rectify and reinstate normal biological processes in the immunological system and eradicate all previously abnormal chemical entities (these would be any chemical medicine) that have been previously administered which result from the unscrupulous chronic use of antibiotics and totally erratic immunization procedures which suppress the immune system and leave it susceptible to any other infection.
- reducing the fatty changes in the bone marrow allows for better red blood cell production.
- reducing the fatty changes in the liver enhances the production of acute phase proteins to combat infections as first line of defense.
- the composition serves to provide improved glycogen production for energy needs and albumin for better egg production.
- composition will conveniently be administered to chickens as a food additive or as a water soluble solution added to drinking water.
- the composition may also be provided and administered as capsules.
- the dosage is calculated at 10g per 100kg live body weight per day for the first week and 2g per 100kg thereafter.
- the combination of the minerals and vitamins help enhance the production of red blood cells and also normalize the ionic charge of the red blood cells to ensure maximum red blood cell homeostasis.
- the composition provides a holistic treatment which in addition to rectifying the immune system also provides improved red blood cell production and overall wellbeing of the chickens.
- the composition activates and resets ionic spheres around the surface of red blood cells to provide improved oxygen concentration.
- the chickens are provided with an improved survival rate through improved capacity to provide oxygen to all the organs.
- Administering antibiotics to the chicken feed from day 1 to day 28 only aggravates the process and has up to now done nothing to counteract or relieve the problems.
- Antibiotics undermine the immune system as a whole and have no curing effect, for this is not an ordinary infection but rather the end result of a Type II immune response.
- the composition provides a first line of defense to the problems described by preventing or deterring against vertical transmissions through the oviduct from the parent stock to the new offspring. Furthermore it serves to stimulate the cellular immunity leg of the immune system, not only in the offspring but to start in the parent stock as well. Reversing the gross fatty infiltration in the liver and especially in the bone marrow is beneficial to stimulate the production of red blood cell in the bone marrow and to normalize liver function. While the research and development has taken place with respect to chickens, it is anticipated that the composition can be used in any animal type as well as in humans.
- the administration of the treatment can either be as a food additive or as a water soluble solution added to the daily intake of water. Alternatively, the composition may be provided and administered as capsules.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Fodder In General (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a composition to assist in the regeneration of the red blood cell mass in the bone marrow and act against adverse fatty changes in the liver and/or bone marrow. The composition includes Lemon oil in combination with oils selected from Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John's Wort oil. A carrier will preferably be selected from Humic Acid or Palm oil and the composition will also include amino acids in the form of Methionine and/or Tyrosine; as well as vitamins and/or minerals selected from Calcium, Magnisium, Zinc, Iron, Copper, Phosphorus, Piridoxine, Folic Acid and Vitamin B12. The invention extends to the use of such a composition in the manufacture of a medicament to assist in the regeneration of the red blood cell mass in the bone marrow and act against adverse fatty changes in the liver and/or bone marrow.
Description
Feeding composition comprising lemon oil
FIELD OF THE INVENTION
The invention relates to a composition which will assist the regeneration of the red blood cell mass in the bone marrow and/or act against adverse fatty changes in both the liver and bone marrow. In particular, the composition is for treatment of poultry and specifically chickens.
BACKGROUND TO THE INVENTION
New research in the poultry industry indicates a vertical transfer of pathogenic organisms from the parent stock to the new eggs being laid. This has a detrimental result on the condition of chicks hatched and delivered to the industry.
At an early stage of embryo development, fatty changes in the liver cells and in the bone marrow account for reduced production of albumin, acute phase proteins and glycogen. The latter is an important energy source needed in the pipping stage, to pierce the egg shell when hatching.
The production of new red blood cells is almost impossible with the infiltration of fat cells in the bone marrow and reduced levels of red blood cell precursors. As a result of fatty changes and the mentioned effects, hatching cannot take place or is at least problematic due to inadequate energy levels for the piercing of the egg shell.
The dormant pathogen infection occurs particularly in the macrophage phagocytic cells of the bone marrow. This has been determined in day-old chickens according to the so-called DMII (Dormant macrophage infestation index).The dormant pathogens are usually activated during episodes of stress. The result is a direct suppressing effect on the whole immune system. This hampers any response to elimination of the underlying infections as well as in dealing with new infections that occur from time to time during the growth phase of the chickens.
These pathogens are bacterial organisms which bind directly to the la antigen locus on the surface of the red blood cell cytoplasmic membrane. This complex forms a hapten to stimulate antibody production. The hapten binds to the complex and with the addition of complement C8 and C9, small holes are dissolved into the cytoplasmic membrane. As a result, hemoglobin leakage from the cytoplasm of the red blood cell which causes depletion of red blood cell hemoglobin.
This leads to gross anemia with secondary heart failure and the production of great amounts of bile and ultimately an enlarged gall bladder. At this stage the red blood cell nuclei are not enclosed in a cytoplasmic membrane and lie loose in
the bone marrow. When in contact with each other, the nuclei form numerous micro-emboli that are dispersed throughout the whole of the body. This gives rise to multi-embolic infarction syndrome which could include the heart, brain, liver and high pulmonary arterial blood pressure with secondary right and later left ventricular failure.
The abovementioned problems have led to massive deaths within the poultry industry, especially the broiler industry, starting from day 29 upwards. If these broilers are not slaughtered before day 34, a producer could be left without any broilers. Poor growth and the suppression of homeostatic metabolic processes has often led to the slaughter of the chicken before the normal 42 day age period which produces the normal 1 .7 kg average chicken. For this reason, the average slaughter weight for broiler chickens can be as low as between 1 and 1 .2 kg. One of the most important factors that dictate the financial viability for the egg producing farmer is not only a stable once a day production of eggs, but also the overall albumin index (Al) of the egg. The Al is measured as the Hough Unit Score = Albumin height / Albumin diameter x 100. The normal range is between 70-90%. Unfortunately the mean average these days can be below the 60% mark, largely due to the abovementioned problems.
The existence of the chicken is overwhelmed by: the attack on the red blood cell haemopoiesis (as seen in the form of a Type II immune response) with ultimate haemolysis of the red blood cells and induced anemia; and the physiological suppression of new cell development in the bone marrow and in the liver as a result of secondary fat infiltration with glycogen energy depletion.
OBJECT OF THE INVENTION It is an object of this invention to provide a composition which will at least partially alleviate abovementioned problems.
SUMMARY OF THE INVENTION
In accordance with this invention there is provided a composition to assist in the regeneration of the red blood cell mass in the bone marrow and act against adverse fatty changes in the liver and/or bone marrow comprising Lemon oil in combination with oils selected from Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John's Wort oil together with a carrier. The invention further provides for the carrier to be selected from Humic Acid or Palm oil; and for the composition to be used for the treatment of poultry and, in particular, chickens.
A further feature of the invention provides for the composition to include amino acids; preferably Methionine and/or Tyrosine.
Further features of the invention provide for the composition to include a combination of vitamins and minerals selected from Calcium, Magnesium, Zinc, Iron, Copper, Phosphorus, Piridoxine, Folic Acid and Vitamin B12.
Further features of the invention provide for the composition to be administered as a food additive or as a water soluble solution added to drinking water. The composition may also be provided and administered as capsules. The dosage is calculated at 10g of the composition per 100kg live body weight per day for the first week and 2g per 100kg thereafter.
In accordance with another aspect of this invention there is provided a use of the above defined composition in the manufacture of a medicament to assist in the regeneration of the red blood cell mass in the bone marrow and act against adverse fatty changes in the liver and/or bone marrow.
DESCRIPTION OF THE INVENTION
The composition in accordance with this invention is made up of a combination of natural essential oils and has as its carrier Natural Humic Acid. The main ingredient is Lemon oil and this is used in combination with other essential oils selected from the group comprising Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John's Wart oil.
The oils are dissolved in 96% Ethanol together with Polysorbate 60. The Polysorbate is added as an emulsifier. It assists in the proper dissolution of the constituent aromatic oils in water to provide the required solution. The solution is sprayed onto the granular Humic Acid. A residue of the oils remains on evaporation of the Ethanol. Methionine and Tyrosine are two amino acids that assist in the regeneration of the heart homeostasis and therefore serve to counteract heart failure. They also have the effect of activating the metabolism as a whole. In this sense, these amino acids break down fatty infiltration and change these molecules in the Krebs cycle into protein.
A mixture of two further amino acids in the form of Arginine and Ornithine together with minerals in the form of Calcium, Magnesium, Copper, Zinc, Iron and Phosphorus and vitamins Pyridoxine, Folic acid and Vitamin B12 are also included.
The Lemon oil provides the composition with the ability to regenerate and/or stimulate new red blood cell production in the bone marrow. The minerals (and/or other electrolytes) that are included in the composition serve to restore red blood cell homeostasis for oxygen delivery to organs.
The composition of this invention is directed on the one hand to rectify and reinstate normal biological processes in the immunological system and eradicate all previously abnormal chemical entities (these would be any chemical medicine) that have been previously administered which result from the unscrupulous chronic use of antibiotics and totally erratic immunization procedures which suppress the immune system and leave it susceptible to any other infection. On the other hand, reducing the fatty changes in the bone marrow allows for better red blood cell production. Also, reducing the fatty changes in the liver enhances the production of acute phase proteins to combat infections as first line of defense. In combination with this, the composition serves to provide improved glycogen production for energy needs and albumin for better egg production.
The composition will conveniently be administered to chickens as a food additive or as a water soluble solution added to drinking water. The composition may also be provided and administered as capsules. The dosage is calculated at 10g per 100kg live body weight per day for the first week and 2g per 100kg thereafter.
The combination of the minerals and vitamins help enhance the production of red blood cells and also normalize the ionic charge of the red blood cells to ensure maximum red blood cell homeostasis.
The composition provides a holistic treatment which in addition to rectifying the immune system also provides improved red blood cell production and overall wellbeing of the chickens. The composition activates and resets ionic spheres around the surface of red blood cells to provide improved oxygen concentration.
Also, by improving the red blood cell mass the chickens are provided with an improved survival rate through improved capacity to provide oxygen to all the organs.
Administering antibiotics to the chicken feed from day 1 to day 28 only aggravates the process and has up to now done nothing to counteract or relieve the problems. Antibiotics undermine the immune system as a whole and have no curing effect, for this is not an ordinary infection but rather the end result of a Type II immune response.
The composition provides a first line of defense to the problems described by preventing or deterring against vertical transmissions through the oviduct from the parent stock to the new offspring. Furthermore it serves to stimulate the cellular immunity leg of the immune system, not only in the offspring but to start in the parent stock as well. Reversing the gross fatty infiltration in the liver and especially in the bone marrow is beneficial to stimulate the production of red blood cell in the bone marrow and to normalize liver function. While the research and development has taken place with respect to chickens, it is anticipated that the composition can be used in any animal type as well as in humans. The administration of the treatment can either be as a food additive or as a water soluble solution added to the daily intake of water. Alternatively, the composition may be provided and administered as capsules.
Claims
1 . A composition to assist in the regeneration of the red blood cell mass in the bone marrow and act against adverse fatty changes in the liver and/or bone marrow comprising Lemon oil in combination with oils selected from
Thyme, Marjoram, Lavender, Rosemary, Cinnamon, Basil and St John's Wort oil together with a carrier.
2. A composition as claimed in claim 1 in which the carrier is Humic Acid.
3. A composition as claimed in claim 1 in which the carrier is Palm oil.
4. A composition as claimed in any one of claims 1 to 3 which is used for the treatment of poultry.
5. A composition as claimed in claim 4 which is used for the treatment of chickens.
6. A composition as claimed in any one of the claims 1 to 5 which includes amino acids.
7. A composition as claimed in claim 6 in which the amino acids comprise of Methionine and/or Tyrosine.
8. A compostion as claimed in any one of claims 1 to 7 which includes a combination of vitamins and/or minerals selected from Calcium, Magnnesium, Zinc, Iron, Copper, Phosphorus, Piridoxine, Folic Acid and Vitamin B12.
9. A composition as claimed in any one of claims 1 to 8 which is administered as a food additive.
10. A composition as claimed in 8 which is administered as a water soluble solution added to drinking water.
1 1 . A composition as claimed in claim 8 which is provided and as administered as capsules.
12. A composition as claimed in any one of claims 5 to 1 1 in which the dosage is calculated at about 10g of composition per 100kg live body weight per day for the first week in a chicken's life.
13. A composition as claimed in claim 12 in which the dosage is calculated at about 2g per 100kg thereafter.
14. Use of a composition as claimed in any one of claims in the manufacture of a medicament to assist in the regeneration of the red blood cell mass in the bone marrow and act against adverse fatty changes in both the liver and/or bone marrow.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201000823 | 2010-02-04 | ||
| ZA2010/00823 | 2010-02-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2011095940A1 true WO2011095940A1 (en) | 2011-08-11 |
Family
ID=44355022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2011/050466 WO2011095940A1 (en) | 2010-02-04 | 2011-02-03 | Feeding composition comprising lemon oil |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011095940A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106615638A (en) * | 2016-09-13 | 2017-05-10 | 中国水产科学研究院淡水渔业研究中心 | Method for reducing fat deposition in livers of Oreochromis niloticus during high-density cultivation |
| CN110050892A (en) * | 2019-03-05 | 2019-07-26 | 厦门汇承科技有限公司 | A kind of enhancing intestinal health and the pig feed additive of weight gain and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9602190A2 (en) * | 1996-08-09 | 1998-05-28 | György Gábor | Pharmaceutical composition against poultry coccidiosis |
| EP1132009A1 (en) * | 2000-02-29 | 2001-09-12 | Nor-Natur ApS | Natural, intestinally active feed additive |
| FR2872683A1 (en) * | 2004-07-12 | 2006-01-13 | Tech Animales Sa Bureau Des | Feed additive used for improving zootechnical performance, e.g. weight gain, of poultry comprises carvacrol encapsulated in enteric dosage form |
| US20070104765A1 (en) * | 2005-11-09 | 2007-05-10 | Faltys Gary L | Livestock and poultry feed additive composition |
| US20080032021A1 (en) * | 2006-05-19 | 2008-02-07 | Faltys Gary L | Feed supplements for ruminants including essential oil compounds and organic acids |
-
2011
- 2011-02-03 WO PCT/IB2011/050466 patent/WO2011095940A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP9602190A2 (en) * | 1996-08-09 | 1998-05-28 | György Gábor | Pharmaceutical composition against poultry coccidiosis |
| EP1132009A1 (en) * | 2000-02-29 | 2001-09-12 | Nor-Natur ApS | Natural, intestinally active feed additive |
| FR2872683A1 (en) * | 2004-07-12 | 2006-01-13 | Tech Animales Sa Bureau Des | Feed additive used for improving zootechnical performance, e.g. weight gain, of poultry comprises carvacrol encapsulated in enteric dosage form |
| US20070104765A1 (en) * | 2005-11-09 | 2007-05-10 | Faltys Gary L | Livestock and poultry feed additive composition |
| US20080032021A1 (en) * | 2006-05-19 | 2008-02-07 | Faltys Gary L | Feed supplements for ruminants including essential oil compounds and organic acids |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106615638A (en) * | 2016-09-13 | 2017-05-10 | 中国水产科学研究院淡水渔业研究中心 | Method for reducing fat deposition in livers of Oreochromis niloticus during high-density cultivation |
| CN106615638B (en) * | 2016-09-13 | 2019-11-22 | 中国水产科学研究院淡水渔业研究中心 | A method of reducing Liver fatty deposition in gift tilapia high-density breeding |
| CN110050892A (en) * | 2019-03-05 | 2019-07-26 | 厦门汇承科技有限公司 | A kind of enhancing intestinal health and the pig feed additive of weight gain and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| González-Parra et al. | Phosphorus and nutrition in chronic kidney disease | |
| CN103315299B (en) | Health-care food with function of enhancing immunity and memory | |
| Baloš et al. | Electrolytes–sodium, potassium and chlorides in poultry nutrition | |
| WO2011027301A1 (en) | Algae spirulina platensis preservation by natural honey | |
| US8716331B2 (en) | Supplement composition and methods of use | |
| JPS61500433A (en) | Treatment of animal diarrhea | |
| CN107440088A (en) | Improve operation, the nutrients and preparation method thereof of chemicotherapy tumor patient immunity | |
| US4839347A (en) | Composition for treating dehydration | |
| CN105901703A (en) | A marine organism type enteral nutrition preparation used for burn patients | |
| Plotnick | Feline chronic renal failure: long-term medical management | |
| WO2011095940A1 (en) | Feeding composition comprising lemon oil | |
| CN104171761A (en) | Feed additive composition for laying hens at egg laying peaks | |
| Morsy | Effect of zeolite (Clinoptilolite) as a salinity stress alleviator on semen quality and hemato-biochemical parameters of Montazah cocks under South Sinai conditions | |
| JP4428553B2 (en) | Prophylactic and / or therapeutic agent for domestic animals | |
| CN105581331A (en) | Calcium supplementing nutrition composition | |
| Özkan et al. | Diagnosis and treatment of hypophosphatemia in young Turkeys | |
| US20150201650A1 (en) | Dietary supplement | |
| CN108567069A (en) | A kind of cultivation domestic animal ganoderma lucidum auxiliary material | |
| RU2505069C1 (en) | Method of application of active carbon feed additive for increasing productivity of laying hens | |
| RU2671635C1 (en) | Composition for stimulating immune-metabolic processes and prevention of diarrhea syndrome of newborn calves | |
| CN105166901A (en) | Nutrient composition for hemodialysis patient | |
| Elnesr et al. | Trace minerals in laying hen diets and their effects on egg quality | |
| RU2617390C1 (en) | Dog treatment method with pyelonephritis and chronic renal insufficiency | |
| US20150051274A1 (en) | Supplement composition and method of use | |
| JP5248438B2 (en) | Ruminant milk production improver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11739477 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11739477 Country of ref document: EP Kind code of ref document: A1 |